The problem of comparing several experimental treatments to a standard arises frequently in medical research. Various multi-stage randomized phase II/III designs have been proposed that select one or more promising experimental treatments and compare them to the standard while controlling overall Type I and Type II error rates. This paper addresses phase II/III settings where the joint goals are to increase the average time to treatment failure and control the probability of toxicity while accounting for patient heterogeneity. We are motivated by the desire to construct a feasible design for a trial of four chemotherapy combinations for treating a family of rare pediatric brain tumors. We present a hybrid two-stage design based on two-dimensional treatment effect parameters. A targeted parameter set is constructed from elicited parameter pairs considered to be equally desirable. Bayesian regression models for failure time and the probability of toxicity as functions of treatment and prognostic covariates are used to define two-dimensional covariate-adjusted treatment effect parameter sets. Decisions at each stage of the trial are based on the ratio of posterior probabilities of the alternative and null covariate-adjusted parameter sets. Design parameters are chosen to minimize expected sample size subject to frequentist error constraints. The design is illustrated by application to the brain tumor trial.
to decide whether E n provides an improvement over S. Design parameters are chosen to minimize expected sample size subject to constraints on overall Type I and Type II error. Schaid et al. (1990) proposed a similar 2-stage design for timeto-event outcomes that allows more than one E j to move forward to stage 2, allows termination of the trial in stage 1 for either futility or superiority, and does pairwise comparisons with the possibility of concluding that more than one E j provides an improvement over S. Many extensions of these designs have been proposed, including designs with more than two stages (Stallard and Todd, 2003; Stallard and Friede, 2008) , a design that continues accrual between stages and uses the stage 1 data to determine the stage 2 sample size adaptively (Liu and Pledger, 2005) , and an algorithm for computing decision boundaries (Cheung, 2008) .
We address the problem of selecting among E 1 , . . . ,E J and comparing the selected treatment to S based on ðT,YÞ, where T is survival or event-free survival (EFS) time and Y indicates a nonfatal severe adverse event (SAE). Thus, death is accounted for by T and not by Y. Our motivation was the desire to provide a feasible design for a trial of four chemotherapy combinations for treating pediatric patients with choroid plexus tumors (CPTs). CPTs include three histological subtypes: choroid plexus carcinoma (CPC), atypical plexus papilloma (APP) and choroid plexus papilloma (CPP). A typical CPT patient is a very young child, with 61% less than three years of age. Because these tumors are too rare for standard protocol designs, to date no clinical trial specific for CPTs has been completed (Wolff et al., 2002) . In the planned trial, the standard treatment is S¼carboplatinþcyclophosphamideþ etoposideþvincristine, and the three experimental treatments are E 1 ¼doxorubicinþcisplatinumþactinomycinþetoposide, E 2 ¼high dose methotrexate and E 3 ¼temozolomideþirinotecan. The outcomes are T¼EFS time, with an event defined as disease progression or death, and Y ¼I(severe toxicity). The baseline covariates are Age and indicators of metastatic disease, whether surgery achieved a complete resection (CR), and the unfavorable CPC histology. The goal is to increase T on average while controlling the probability of toxicity, compared to standard therapy, while also accounting for patient heterogeneity.
We propose a hybrid two-stage select-and-test design based on (T,Y) and baseline covariates. The logic of our design mimics that of the TSE design, with design parameters chosen to minimize expected sample size subject to overall Type I and Type II error constraints. The main differences between our procedure and the TSE design are that (i) we account for patient heterogeneity, (ii) we base the tests on two-dimensional covariate-adjusted treatment effect parameters, and (iii) we take a Bayesian geometric approach in which test statistics are constructed from posterior probabilities of two-dimensional parameter sets, rather than using conventional Z-scores.
Overview of the methodology

The basic idea
To establish the ideas underlying the geometric construction, for simplicity we temporarily consider the special case of two treatments, with j ¼0 and 1 for S and E, and we ignore covariates. The parameters y Y,j and y T,j represent average behavior of two different outcomes. In the CPT trial, the physician decided to use y Y,j ¼the probability of toxicity and y T,j ¼ PrðT 4 24 monthsÞ with treatment j as the parameters, where T is the time to treatment failure, defined as disease progression or death. Alternatively, the physician might use the mean of median of T as y T,j . Thinking of h j ¼ ðy Y,j ,y T,j Þ as a two-dimensional parameter that describes the average behavior of the outcomes (Y,T) with treatment j, the problem of comparing E to S becomes that of comparing h 1 to h 0 .
In such settings, there are many methods for dimension reduction to obtain a one-dimensional decision criterion. Our approach exploits a Bayesian formulation and subjective goals of the physician, using the following construction. Let l 0 ¼ ðm Y,0 ,m T,0 Þ be the prior mean of h 0 based on experience with S. We elicit a set of fixed target pairs, fh e,1 , . . . ,h e,m g, for h E that the physician considers equally desirable improvements over l 0 . We then form the polygonal line L connecting the elicited values, and define the target parameter set, Y L , of all h pairs at least as desirable as a pair on L. The test is based on the posterior probability of Y L compared to the posterior probability of the null set Y 0 where y Y Z m Y,0 and y T r m T,0 .
Accounting for covariate effects requires the additional steps of fitting regression models, obtaining covariate-adjusted treatment effects, and transforming Y 0 and Y L . This adds technical complications to the construction, but the essential idea is still to base tests on posterior probabilities of two-dimensional parameter sets. For the CPT trial, the target line and target parameter set in terms of ðy Y,j ,y T,j Þ are given in Fig. 1 . In other settings with two outcomes, this construction may be carried out in the same way, but using different parameters. For example, in a phase I/II dose-finding trial based on indicators of toxicity and response, y T,j would be replaced by the response probability.
Model and parameters
We define the distribution of T conditional on Y to allow the possibility that toxicity may affect the event time. Let n denote the vector of model parameters. For a patient with baseline covariates Z ¼ ðZ 1 , . . . ,Z q Þ given treatment j ¼ 0; 1, . . . ,J, denote the probability of toxicity by y Y,j ðZ,nÞ ¼ PrðY ¼ 19j,Z,nÞ and the conditional probability density function and survivor function of T given Z and Y by f j ðt9Z,Y,nÞ and F j ðt9Z,Y,nÞ ¼ PrðT 4t9j,Z,Y,nÞ. Denoting the time to the event or independent right censoring by T 
and y Y,j ðZ,nÞ is a function of the linear term
where b Y and b T are covariate effects. Expression (2) specifies the conditional distribution of ½T9j,Y,Z, with b T,q T þ 1 the effect of toxicity on the distribution of T. Expression (3) specifies the marginal distribution of ½Y9j,Z. The parameter g T,j is the effect of treatment j on T after adjusting for Y and Z, and g Y,j is the effect of treatment j on Y after adjusting for Z. Thus, the parameter vectorc ¼ ðc 0 ,c 1 , . . . ,c J Þ may be considered a 2ðJ þ 1Þ-dimensional, covariate-adjusted generalization of the (Jþ1)-dimensional parameter vectorh ¼ ðy 0 ,y 1 , . . . ,y J Þ given earlier in the univariate setting. For each E j , we define the
are more desirable. The test statistics will be defined in terms of 2J-dimensional parameter vectord ¼ ðd 1 , . . . ,d J Þ.
Steps of the construction
We first list the steps required to construct the test statistics. Additional details are given in Sections 3 and 4. Let H denote the set of all possible values taken on by the h j ðZ,Y,nÞ pairs, and denote the set of all possible d j 's by D. Since y T,j ðZ,Y,nÞ is defined conditional on the toxicity outcome Y, in the following construction targets are elicited for each value y n ¼ 0; 1 of Y and averaged to obtain a set of targets that do not depend on Y. 5. The test statistics used in each stage of the trial are the posterior probability ratios
Under the construction, larger R j (data) corresponds to greater superiority of E j over S. 
Model and parameters for the CPT trial
The CPT trial design initially was motivated by the physician's desire to use (Y,T) as the outcome, and to study several experimental regimens. The physician chose to use the probability of toxicity and PrðT 4 24 monthsÞ as the reference parameters, and considered T to be independent of Y, so the formulation was simpler than that given above. Specifically, b T,q T þ 1 0 in (2), and only one set of target pairs was elicited in step 2 of the construction. The covariates used in the CPT trial, given in Table 1 , are well-known to be related to event-free survival time for this disease and were specified by the physician.
Denoting I 7 ðAÞ ¼ þ1 if event A occurs and -1 if not, to obtain Z T,j ðZ T ,Y,nÞ and thus g T,j , we defined the four binary covariates Z T,1 ¼ I 7 ðAge Z 3Þ,Z T,2 ¼ I 7 (metastatic disease), Z T,3 ¼ I 7 (surgery achieved a CR), and Z T,4 ¼ I 7 (histology¼CPC). Using these, the physician specified the reference patient to be 2 years old, with non-metastatic disease, surgical CR, and CPC histology, denoted by z n ¼ ðÀ1,À1, þ 1, þ 1Þ. In contrast, the probability of toxicity only varied with Age, and was modeled using the
logðAgeÞ. Details of how this function was determined from elicited values are provided in Section 6. While eliciting the target pairs for the CPT trial from the physician, we used a graphical representation of preliminary versions of Fig. 1 , and modified the figure adaptively as he adjusted some values based on the figure. The process for obtaining the h target pairs thus was straightforward. Initially, the shape of L was surprising. When we questioned this, the physician explained that this L very accurately reflects his strong belief that a very high risk of toxicity is an acceptable trade-off for a high probability of achieving a longer event-free survival time in CPT patients. 
Table 1
Historical population percent and elicited prior event-free survival (EFS) time probabilities for each of 16 patient prognostic subgroups defined in terms of age, whether the tumor was metastatic at first diagnosis (MET), whether surgery achieved a complete resection (CR), and the unfavorable histology choroid plexus carcinoma (CPC). In general, T is not reduced to the binary indicator of the event ðT 4 t n Þ, and all right-censored event time data ðT o ,EÞ are included in the likelihood and used to compute the posteriors that determine the test statistic. In the CPT trial, while y T,j ðZ,Y,nÞ ¼ F j ðt n 9Z,Y,nÞ for reference time t n ¼24 months is used as the basis for defining targets and hypotheses (described below in Section 3), T is not reduced to the binary indicator of the event ðT 4 24Þ.
A geometry for comparing treatments
In this section, we provide details of the method for constructing two-dimensional parameter sets that provide a geometric basis for treatment comparison. Given null pair l h,0 , a set of elicited target pairsh e and target set Y L are admissible if (i) l h,0 = 2Y L and (ii) y Y is a strictly increasing function of y T for h 2 L. We require these admissibility conditions to avoid cases that do not make sense. These conditions can be ensured easily during the target pair elicitation process by showing the physician a plot of l h,0 and the elicited targets. The sample size, Type I error, and generalized power of the test, defined below in Section 5, depend on the shape of L and the distance between l h,0 and L. Similar to a conventional test of a one-dimensional parameter, in the present setting the sample size required to achieve given Type I error and generalized power would be larger for L closer to l h,0 . Condition (ii) rules out the possibility that some portions of L may be either horizontal or vertical line segments. For example, if L were allowed to contain a horizontal line segment, then there would be parameter pairs, h and h 0 , both on that horizontal segment such that y T o y
Y . This would say that, despite the fact that h 0 has greater efficacy than h and the two pairs have identical toxicity, they are considered equally desirable, which is nonsense. In particular, ''staircase'' shaped L are inadmissible. This construction is illustrated for the CPT trial by Fig. 1 . While we assume that T may depend on Y, it may be argued either that toxicity (Y ¼1) decreases the mean EFS time since CPT patients who experience toxicity may have their chemotherapy dose reduced or, instead, that toxicity increases mean EFS time due to a positive association between toxicity and cancer cell killing by the chemotherapy. For the CPT trial, it was not necessary to average two sets of targets, described earlier, since the physician considered T to be independent of Y. 
A hybrid select-and-test design
Priors
Our formulation utilizes available information on covariate effect parameters, obtained by elicitation or from historical data. In contrast, we assume non-informative iid priors on the treatment effect pairs c 0 ,c 1 , . . . ,c J because comparative E j -versus-S decisions will be based on the posteriors of d 1 , . . . ,d J . While it may be argued that the prior on c 0 should be informative to reflect historical experience with S, we do not make this assumption in order to avoid confounding treatment effects based on the trial data with effects of latent variables that may differ in distribution between the trial and historical data. Under the assumption of no treatment-covariate interactions, any differences in the covariate effects ðb T ,b Y Þ between prior experience and the trial would be manifested approximately additively in the linear terms (3) and (2) for all j ¼ 0; 1, . . . ,J. Hence such differences would introduce additional variability but each d j will be approximately unbiased. Our formulation ensures that the treatment comparisons will be dominated by the data from the trial, with at most numerically trivial effects due to the non-informative priors on the c j 's. 
Hypotheses and trial design
During the trial, each patient's Z vector is recorded at enrollment, and a treatment j is randomly chosen using the Pocock-Simon method (1975) to balance on Z. The treatment is administered and the patient's outcome ðY,T o ,EÞ is observed. In stage 1, let data 1 denote the data available when the decision is made and denote the index of the empirically best experimental treatment at the end of stage 1 by n ¼ argmaxfj ¼ 1, . . . ,J : R j ðdata 1 Þg. Let M 1 be the number of events observed and r 1 the decision cut-off for the test statistic R n ðdata 1 Þ. When the decision is made in stage 2, denote the data from all patients in arms E n and S from both stages by data 2 , let M 2 denote the total number of events observed from both treatment arms E n and S, and let r 2 denote the decision cut-off for the test statistic R n ðdata 2 Þ. Given ðM 1 ,M 2 ,r 1 ,r 2 Þ, the trial is conducted as follows: Stage 1. Randomize patients among E 1 , . . . ,E J and S until M 1 events have been observed. The stage 1 decision is made when Y has been evaluated for all stage 1 patients enrolled up to time t 1 . If R n ðdata 1 Þ 4r 1 then continue to stage 2; otherwise, terminate the trial and accept H 0 .
Stage 2. Randomize patients between E n and S until M 2 additional events from patients in these two arms have been observed. The final decision is made when Y has been evaluated for all patients. If R n ðdata 2 Þ 4 r 2 then accept H a,n ; otherwise accept H 0 .
Since at most one E j may be selected in stage 1, the design allows the J þ 1 possible conclusions H a,1 , . . . ,H a,J , that of the E j 's is sufficiently promising for stage 2 evaluation, or H 0 , that no E j is promising and the trial should be stopped. If the trial continues to stage 2, the data from patients enrolled in stage 1 are utilized when computing the stage 2 statistic R n ðdata 2 Þ for the final decision. In particular, some of the M 2 additional events observed in stage 2 may come from patients enrolled in arms E n or S in stage 1. Let t n Y be the length of the time period from the start of therapy during which toxicity is monitored, which is 4 months for the CPT trial. Because Y is a binary variable based on a 4-month observation period, Y ¼1 may be scored at any time toxicity occurs up to t n Y but Y ¼0 may be scored only after the patient has been observed for a period of length t 
Operating characteristics
While the design uses Bayesian decision criteria, in practice it must have good frequentist properties. To define overall Type I and Type II error, we generalize the approach taken by TSE in the simpler case of one-dimensional parameters y 0 ,y 1 , . . . ,y J 2 R 1 , without covariates. As a frame of reference for what follows, we first briefly review the TSE formulation.
The E j -versus-S effects are d j ¼ y j Ày 0 for j ¼ 1, . . . ,J, the null set is D 0 ¼ ðÀ1, 0 and the alternative set is D a ¼ ½d n , þ1Þ for fixed d n 4 0. The global null hypothesis is H a,j . The Type I error is the probability of concluding H a when H 0 is true. The generalized power (GP) is the probability that, for some j such that H a,j is true, one correctly concludes H a,j . TSE show that, subject to the requirements (i) We define Type I error and GP similarly, but now the hypotheses refer to the parameter sets D 0 and D L in R 2 . For each j ¼ 1, . . . ,J, the event that the design concludes H a,j is A j ¼ fnðdata 1 Þ ¼ j, R j ðdata 1 Þ 4 r 1 and R j ðdata 2 Þ 4 r 2 g, ð5Þ
and the event that the global alternative H a is accepted is A ¼ S J j ¼ 1 A j ¼ fR n ðdata 1 Þ 4r 1 and R n ðdata 2 Þ 4 r 2 g. The event that the design accepts H 0 is A 0 ¼ fR n ðdata 1 Þ r r 1 g [ fR n ðdata 1 Þ 4r 1 and R n ðdata 2 Þ r r 2 g: ð6Þ
Denote a 2J-vector of J fixed treatment effect pairs byd
We make a strong distinction between such fixed parameter vectors, which will be used to evaluate the design's properties, and the random parameter vectord under the Bayesian model. In our setting, the GP is the probability fðd n Þ of correctly concluding H a,j for a true parameter vectord n for which d n j 2 D L . In order to define practical criteria for making decisions and deriving design parameters the following theorem is needed, which may be considered a two-dimensional version of the theorem in (TSE) (1988) . Similar to the onedimensional case, we impose the requirement that all d n j must be in either D L or D 0 since no statistical procedure can reliably distinguish between parameters that are arbitrarily close. n Þ, and we will call such a vector that minimizes the GP a LFC. Similarly, the Type I error is the maximum over d n 2 D 0 of the probability of rejecting H 0 , given by a
n ¼0Þ, where0 is the 2J-vector with all entries 0. Let a be the design's largest allowed probability of a Type I error and f the smallest allowed probability of making a correct decision under H a . Let zðd n Þ ¼ PrfR n ðdata 1 Þ rr 1 9d n g denote the probability of early termination after stage 1, and let z be the maximum allowed value of z under an LFC. In order to feasibly obtain an optimal design, f and z are evaluated at the m transformed target pairs fd e,1 , . . . ,d e,m g that determine D. The design requires the Type I error constraint a n r a, the incorrect early stopping probability constraint
e,r Þg r z
and the GP constraint
The design parameters are thus fa,f,z,M 1 ,M 2 ,r 1 ,r 2 g.
Deriving optimal design parameters
While fa,f,zg are predetermined, fM 1 ,M 2 ,r 1 ,r 2 g must be derived. As with any group sequential design based on event times where decisions are made when specified numbers of events are observed, the sample sizes N 1 and N 2 in stages 1 and 2 are random quantities determined by the design's required event counts, M 1 and M 2 , and the underlying accrual and event rates. The total sample size, N, is either N 1 or N 1 þ N 2 , with mean EðNÞ ¼ EðN 1 Þþð1ÀzÞEðN 2 Þ, which may be computed under the nulld n ¼ 0 or at an LFC. Subject to the constraints f n Z f, a n ra and z n rz, we derive the fM 1 ,M 2 ,r 1 ,r 2 g values that minimize the equally weighted mean overall sample size EðNÞ ¼ 
Numerical methods
For each fixed d n , we obtained the optimal fM 1 ,M 2 ,r 1 ,r 2 g for the CPT trial by searching in three nested loops, with M 1 in the outer loop, M 2 nested within M 1 , and ðr 1 ,r 2 Þ nested within M 2 . For each fM 1 ,M 2 ,r 1 ,r 2 g examined, given the assumed true valuẽ d n , we computed f n , z n , a n and the objective function EðNÞ by generating 2000 data sets from the likelihood with parameters corresponding to ð0, . . . ,0,d n Þ. During the search, a design was considered possible if it satisfied the three error constraints. Initially, a small number of ðM 1 ,M 2 Þ pairs were considered. For each ðM 1 ,M 2 Þ pair, a local grid search was done in ðr 1 ,r 2 Þ starting with a coarse grid having increments 0.10 to identify possible solutions, then picking the possible ðr 1 ,r 2 Þ pair giving the smallest value of EðNÞ, then localizing the grid around that pair and refining the grid increments to 0.01. This was repeated with the grid of ðr 1 ,r 2 Þ values refined to increments of 0.001. For each evaluation of ðf n ,z n ,a n ,EðNÞÞ at a pair of ðM 1 ,M 2 Þ values, if there were no ðr 1 ,r 2 Þ pairs giving a possible solution, M 2 was incremented to M 2 þ 1, with this limited to at most 20 steps. Similarly, given M 1 , if no M 2 yielding a possible solution was found then M 1 was incremented to M 1 þ1, with this repeated until a possible solution was found. Once a set of possible designs were obtained, the ðM 1 ,M 2 Þ grid was localized at the pair ðM 1 ,M 2 Þ o minimizing EðNÞ and an exhaustive search was done in a contiguous set of pairs around ðM 1 ,M 2 Þ o .
To simulate each data set when applying the above algorithm, each patient's Z was sampled from the historical covariate distribution (''Popn. Percent'' in Table 1 ) and a treatment j was then randomly chosen based on Z using the Pocock-Simon method (1975) . The toxicity indicator Y was simulated first using the probability y Y,j ðZ,nÞ, substituting the 
For each simulated data set, the stage 1 posterior probability ratios R 1 ðdata 1 Þ, . . . ,R J ðdata 1 Þ were computed, the best stage 1 treatment index nðdata 1 Þ was identified, the stage 2 test statistic R n ðdata 2 Þ was computed, and the decision rules were then evaluated. Our construction involves a large number of nuisance parameters. While misspecifying these values may result in error inflation, we have used prior means, since these were the best available numerical values.
The values of R j ðdata 1 Þ and R j ðdata 2 Þ were computed numerically using Markov chain Monte Carlo with Gibbs sampling (Robert and Cassella, 1999) . For prior pðnÞ, each generated chain fn ð1Þ , . . . ,n ðKÞ g had K ¼ 10; 000 samples distributed in proportion to the posterior integrand, Likðdata,nÞ Â pðnÞ. The first sample vector n ð1Þ in each chain was set equal to the mode of the integrand, found using the Nelder-Mead algorithm (1965).
Establishing priors for the CPT trial
Since clinical experience with CPT (Wrede et al., 2005 (Wrede et al., , 2007 indicates that the hazard function for EFS is certainly nonconstant and very likely non-monotone, we assumed that ½T9Z,j is lognormally distributed with EflogðTÞ9Z,jg
To determine numerical values of the hyperparametersñ T of the prior pðn T 9ñ T Þ, we proceeded as follows. Table 1 . We assumed that b T,1 , . . . ,b T,4 are normally distributed with common variance, and that logðs T Þ is normal. Indexing the elicitation times by r ¼ 1; 2,3; 4 and the covariate vectors by l ¼ 1, . . . ,16, and regarding each prior mean EFS probabilitỹ
as a function ofñ T , a generalization of the method of Thall and Cook (2004) independently from each of three oncologists with extensive experience treating patients with CPTs. The sets of elicited toxicity probabilities, shown in Fig. 1 , were remarkably consistent in that all three physicians gave values that described the same non-monotone function of Age in which the probability of toxicity is high for infants, very low for patients 3-50 years of age, and moderately higher for older patients. While most CPT patients are very young, the age domain used in the elicitation is appropriate for the trial because its eligibility is not restricted to children, and CPT patients can be as old as 80 years. Denoting the elicited probability at the rth age from the lth physician by y ðeÞ Y,l,r , these values were fit as a function of Age by considering mixed models with fractional polynomial linear terms (Royston and Altman, 1994) taking the general form logitfy
,r ð2Þ ,r ð3Þ are iid Nð0,s 2 r Þ physician effects, and the E l,r 's are iid Nð0,s 2 E Þ residuals. One best fitting model to use as a basis for constructing a design was determined following the approach recommended by Sauerbrei and Royston (1999) . This was done by varying the exponents p 1 and p 2 exhaustively over the set fÀ2,À1,À0:5,0,0:5,1; 2,3g, where the exponent ''0'' corresponds to logðAgeÞ. The 28 models of the above form with p 1 ap 2 , and the eight models not including the term b Y,2 Age p 2 , were considered. Each of these 36 models was fit both with and without physician effects, for a total of 72 models. The Bayesian Information Criterion (BIC, Schwarz, 1978) values ranged from 85.5 to 140.2 for the 72 models, with the best fitting model given by the linear term including Age 1=2 and logðAgeÞ. Fig. 3 gives the plots of these three sets of elicited toxicity That is, the mean probability that T 424 months for the reference patient z n was 0.47, and based on the elicited age-dependent toxicity probabilities the mean probability that a 2-year-old patient would suffer toxicity was 0.11.
Design parameters for the CPT trial
Optimal designs
The optimal designs with a ¼ 0:05, f ¼ 0:80 and z ¼ 0:05 were derived for J¼1,2, and 3. The case J¼1 is a two-arm, two-stage design that uses the same geometric construction but only compares one E¼E 1 to S based on d ¼ d 1 . In this case, the null hypothesis is H 0 : d 2 D 0 and there is one alternative, H a,1 ¼ H a : d 2 D L . This case was included as a basis for comparison to assess the effects of having to perform a selection in stage 1.
The optimal designs are given in Table 2 . It is important to bear in mind that the test cutoffs r 1 and r 2 pertain to the posterior probability ratios Rðdata 1 Þ and Rðdata 2 Þ, and not to conventional Z-scores. The numbers of events required to make decisions in each stage, M 1 and M 2 , increase substantially with J due to the facts that, with larger J, more treatments are evaluated and the stage 1 decision includes selection among the E j 's as well as comparison to S. This produces increases in overall expected sample size and trial duration with J, although these values also vary greatly with the case under which they were computed. The GP, f n , follows a U-shaped pattern as the true h n moves along L, as illustrated by 
Robustness
To examine robustness of the method to the assumed lognormal distribution for T, we evaluated the design's behavior with T contaminated by multiplicative noise. For the design with J¼3, in each case of true h n in Table 2 we simulated samples of the event times with each T i replaced by G i T i , where the G i 's were independent gamma random variables with mean 1 and variance s 2 G . This had the effects of both changing the distribution of T i and increasing its variability. Denoting
the effect of multiplying T i by G i is to increase the standard deviation s T by the multiplicative factor s GT =s T ¼ ðs Table 3 gives the values of f n , PET, and E(N) for s G ¼ 0, corresponding to the assumed lognormal distribution, and s G ¼ 0:2, 0.4, and 0.6, corresponding to successively larger amounts of contamination. As shown in Table 3 , for s G ¼ 0:4 or 0.6 the value of s GT =s T may be quite large, and it varies substantially depending on the value of the true target pair h n where the design is evaluated. The Type I error and GP hold up quite well even when there is substantial contamination, with f n decreasing substantially only at Targets 2, 3, or 4 for large values s GT =s T Z1:39. Thus, the method appears to be robust to all but extreme departures from the lognormal assumption. 
Table 3
Robustness of the optimal design for J ¼3 experimental treatments to multiplicative contamination of T by a gamma noise variable G with mean 1 and standard deviation (sd) s G . The observed event time is GT, and the ratio s GT =s T ¼ s GT =0:93 is the multiplicative factor by which the sd of T is increased by G. 
Discussion
The proposed design is a hybrid in that Bayesian machinery is used to obtain decision rules, while the design's parameters are derived to ensure that it has specified frequentist properties. The methodology requires a substantial effort to elicit target parameter pairs and priors, and the process of deriving design parameters is computationally intensive.
While these may be considered limitations, the two-dimensional covariate-adjusted target set D L provides a much more refined goal than the conventional approach of increasing median EFS by a given amount while ignoring toxicity and patient covariates. From a practical perspective, the result of applying this design is a sample size small enough to allow the CPT trial to be completed in a realistic timeframe.
There are many other possible approaches to the problem we have addressed here. With regard to controlling error rates, a referee has pointed out that one may take an alternative approach since, if the hypothesis for treatments excluded at the interim analysis are retained, one can consider the disjunctive power to reject a false hypothesis and the familywise error rates to reject a true hypothesis. Aside from the preliminary selection, one might simultaneously use a noninferiority test for safety and a superiority test for efficacy, or use a positive quadrant test, as given by Jennison and Turnbull (1993) . However, these methods do not account explicitly for the relative importance of disease-free survival time and toxicity, which was our primary motivation for using the geometric construction, based on elicited target parameter pairs. Alternatively, one might use a utility score to combine the two outcomes, although this would require dealing with the fact that T has domain ½0,1Þ. One might also use adaptive combination tests (cf. Bretz et al., 2009) , which allow a variety of interim decision rules, including Bayesian rules. Our proposed methodology controls the Type I error under the global null, H 0 , which is a strong requirement since it may be the case that some d j ¼ 0 but others not. In this regard, adaptive combination tests guarantee control of the Type I error for any configuration of nulls. As a future exercise, it would be worthwhile to investigate how such alternative approaches compare to that given here.
Our method relies on the strong assumption that there are no treatment-covariate interactions. We assume this in order to control the number of parameters so that we may obtain a feasible design that can actually be used. The model might be extended to include treatment-covariate interactions, for example in terms of subgroups r ¼ 1, . . . ,K determined by Z, by replacing the linear terms with the 2ðJ þ 1ÞK treatment-subgroup effects Z Y,j,r ðnÞ and Z T,j,r ðnÞ. The number of parameter pairs would then be KðJ þ 1Þ, far too large to implement the methodology practically, since the potential hypotheses and tests would be far more complex. Even with only K ¼2 subgroups, with J¼3 there would be a total of eight treatment-subgroup parameter pairs.
If the trial's entry criteria are sufficiently restrictive that it is reasonable to assume patients are homogeneous with respect to the outcome (Y,T), then the parametric functions would take the simpler form h j ðY,nÞ ¼ ðy T,j ðY,nÞ,y Y,j ðnÞÞ for all patients in treatment arm j. In this case, Z Y,j ðZ,nÞ ¼ g Y,j and Z T,j ðZ,nÞ ¼ g T,j þbY, and the target pairs that determine the alternative region H L would be elicited without reference to covariates. Finally, if it is realistic to assume that T is independent of Y, as in the CPT trial, then Z T,j ðZ,nÞ ¼ g T,j .
